Evidence map›Paper›PMID 33824463›Full record

ArticleLeukemia2021

Hematopoietic stem progenitor cells lacking HLA differ from those lacking GPI-anchored proteins in the hierarchical stage and sensitivity to immune attack in patients with acquired aplastic anemia.

Takeshi Yoroidaka, Kohei Hosokawa, Tatsuya Imi, Hiroki Mizumaki, Takamasa Katagiri, Ken Ishiyama, Hirohito Yamazaki, Fumihiro Azuma, Yasuhito Nanya, Seishi Ogawa and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. When does a PNH clone have clinical significance?Hematology. American Society of Hematology. Education Program · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Takeshi Yoroidaka *Department of Hematology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Kohei Hosokawa *Department of Hematology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.ORCID http://orcid.org/0000-0002-3423-1523
Tatsuya ImiDepartment of Hematology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.ORCID http://orcid.org/0000-0002-7674-7368
Hiroki MizumakiDepartment of Hematology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Takamasa KatagiriClinical Laboratory Sciences, Kanazawa University Graduate School, Kanazawa, Japan.
Ken IshiyamaDepartment of Hematology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.ORCID http://orcid.org/0000-0002-6189-0620
Hirohito YamazakiDivision of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.ORCID http://orcid.org/0000-0003-3018-2098
Fumihiro AzumaHLA laboratory, Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Yasuhito NanyaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Shinji NakaoDepartment of Hematology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan. snakao8205@staff.kanazawa-u.ac.jp.ORCID http://orcid.org/0000-0002-9674-624X
Kanazawa University · JPKyoto University · JPJapanese Red Cross Society, Japan · JPKanazawa University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To characterize glycosylphosphatidylinositol-anchored protein-deficient (GPI[-]) and HLA-class I allele-lacking (HLA[-]) hematopoietic stem progenitor cells (HSPCs) in acquired aplastic anemia (AA), we studied the peripheral blood (PB) of 56 AA patients in remission who possessed both (n = 13, Group A) or either GPI(-) (n = 34, Group B) and HLA(-) (n = 9, Group C) cell populations. Seventy-seven percent (10/13) of Group A had HLA(-) cells in all lineages of PB cells, including platelets, while only 23% (3/13) had GPI(-) cells in all lineages, and the median percentage of HLA(-) granulocytes in the total granulocytes (21.2%) was significantly higher than that of GPI(-) granulocytes (0.28%, P < 0.05). The greater lineage diversity in HLA(-) cells than in GPI(-) cells was also seen when Group B and Group C were compared. Longitudinal studies of seven patients in Group A showed a gradual decrease in the percentage of HLA(-) granulocytes, with a reciprocal increase in the GPI(-) granulocytes in four patients responding to cyclosporine (CsA) and an increase in the HLA(-) granulocytes with a stable or declining GPI(-) granulocytes in three patients in sustained remission off CsA therapy. These findings suggest that HLA(-) HSPCs differ from GPI(-) HSPCs in the hierarchical stage and sensitivity to immune attack in AA.

Indexed as

AdultAgedAged, 80 and overAnemia, AplasticCyclosporineFemaleFollow-Up StudiesGPI-Linked ProteinsGranulocytesHematopoietic Stem CellsHLA AntigensHumansImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesCyclosporineGPI-Linked ProteinsHLA AntigensImmunosuppressive Agents

Identifiers

PMID33824463
OpenAlexW3144394462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.